期刊文献+

Lowry法测定重组人血清白蛋白-白细胞介素2融合蛋白含量的方法验证 被引量:2

The study on Methodology Validation of Recombinant Human Serum Albumin Interleukin 2 Fusion Protein by Lowry Method
下载PDF
导出
摘要 试验验证了Lowry法测定重组人血清白蛋白-白细胞介素2融合蛋白含量的方法,为后续试验提供重组人血清白蛋白-白细胞介素2融合蛋白含量的检测方法。以蛋白含量测定国家标准品为标准品,在100~0μg/m L浓度范围内建立标准曲线,线性关系良好,相关系数(R^2)大于0.99。标准曲线上至少6点(包含两端)满足准确度介于95.2%~111.67%,标准曲线下限准确度介于95.98%~103.6%。高、中、低质量浓度(80,40,20μg/m L)质控样本批内精密度均介于1.51%~4.41%,批间精密度均介于3.83%~6.36%。综合上述信息,Lowry法测定重组人血清白蛋白-白细胞介素2融合蛋白含量的方法稳定,可重现。重组人血清白蛋白-白细胞介素2在200~10μg/m L质量浓度范围内均一。 This test verifies the Lowry method which determines the content of recombinant fusion protein human serum albumin-interleukin 2,and provides a method that can determine the content of recombinant fusion protein human serum albumin-interleukin 2 for the following experiment. Methods: In the experiment of determination of protein content,national standard protein was measured as the standard,in the concentration range of 100~0 μg/m L we create a standard curve with good linear correlation and the coefficient(R^2) is greater than 0.99. Results: The standard curve contains six points(both ends inclusive) at least and it can satisfy the accuracy ranged from 95.2%~111.67%,and the accuracy of the lower limit of the standard curve is between 95.98%~103.6%. The precisions of protein concentration(high,middle,low) of samples were between 1.51%~4.41%. The precisions between three batches were 3.83%~6.36%. The Lowry method for protein concentration of human serum albumin-interleukin 2 fusion is stable and repeatable. The data of protein concentration between 200~10 μg/m L were stable.
作者 黎勇 尹海燕
出处 《农产品加工》 2016年第10期42-44,47,共4页 Farm Products Processing
关键词 lowry法 蛋白浓度 方法学验证 lowry method protein concentration method validation
  • 相关文献

参考文献4

二级参考文献15

  • 1张培培,杨化新,徐康森.高效液相色谱法测定重组人生长激素的蛋白含量[J].药物分析杂志,1994,14(5):31-33. 被引量:2
  • 2李佩,姬美蓉.白介素-11研究新进展[J].国外医学(输血及血液学分册),1995,18(4):221-224. 被引量:1
  • 3.中国生物制品规程.[S].,2000..
  • 4Lorenz J, Wilhelm K, Kessler M,et al. Phase I trial of inhaled natural interleukin - 2 for treatment of pulmonary malignancy :toxicity, pharmacokinetics, and biological effects. Clin Cancer Res, 1996,2 ( 7 ) :1115.
  • 5Skubitz KM, Anderson PM, Zein NN,et al. Inhalational intedeukin -2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drug,2000,11 (7) :555.
  • 6Ten RM, Anderson PM. Interleukin - 2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol,2002,2(2 -3) :333.
  • 7.Chinese Requirements for Biologics(中国生物制品规程)[Z].,2000..
  • 8Frank J K, C, ert Storm. Development of a routine analysis method for liposome encapsulated recombinant interleukin - 2. y Chromatogr,1998,716:285.
  • 9Cadee J A, Groot C J de,Jiskoot W ,et al. Release of recombinant human interleukin - 2 from dextran - based hydrogels. J Controlled Release,2002,78 : 1.
  • 10QIANYu-kun(钱玉昆).New Technology of Immunology(实用免疫学新技术)[M].Beijing(北京):Peking Union Medical College and Bei,1994.49.

共引文献5

同被引文献25

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部